MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (?)
Ratings Breakdown: 1 Hold Rating(s), 10 Buy Rating(s)
Consensus Rating:Buy (Score: 2.91)
Consensus Price Target: $117.82 (116.94% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016JMP SecuritiesReiterated RatingBuy$127.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Jefferies GroupReiterated RatingBuy$119.00 -> $80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Chardan CapitalLower Price TargetBuy$115.00 -> $93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$111.00 -> $81.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$107.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Deutsche BankSet Price TargetBuy$155.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Canaccord GenuityReiterated RatingBuy$160.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Janney Montgomery ScottInitiated CoverageBuy$139.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015BarclaysInitiated CoverageOverweight$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.66)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414($0.60)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.56)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.54)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.14)($1.08)($1.11)
Q2 20164($1.32)($1.19)($1.26)
Q3 20164($1.35)($1.25)($1.30)
Q4 20164($1.41)($0.96)($1.26)
(Data provided by Zacks Investment Research)
Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateHeadline
06/24/16 02:24 PMPrice Target Update on Alnylam Pharmaceuticals (NASDAQ:ALNY) - Trade Calls
06/24/16 02:24 PMAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 02:24 PMCovering the Bases on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Where is the Stock Going? - Press Telegraph
06/24/16 09:28 AMRNA Interference (RNAi) Drug Delivery Market : Growth, Development, and Outlook 2021
06/23/16 09:52 PMPorphyria (Erythropoietic Protoporphyri) Pipeline Market Global Forecast Analysis Research
06/23/16 09:52 PMAlnylam Pharmaceuticals Inc. (ALNY) is Trading Lower on Unusual Volume for June 21
06/23/16 03:55 PMAmyloidosis Pipeline Still Looks To Alnylam For Answers - Seeking Alpha
06/23/16 03:39 PMAlnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Service Day - [at noodls] - 06.23.2016 - Alnylam Community Gives Back in the Communities it Serves at Ten Local Non-Profit Organizations - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading ...
06/23/16 03:30 PMAlnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual “Helping Hands” Community Service Day - [Business Wire] - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that over 400 of its employees participated in a company-wide community service day today to benefit ten local non-profit organizations including: Boston Nature Center, Cradles to Crayons, Emerald Necklace Conservancy, Friends of Alewife, Habitat Education Center, IMEC America, Cupboard of Kindness, Norton Conservation ...
06/22/16 07:37 PMAlnylam Pharmaceuticals Inc. (ALNY) is Trading Lower on Unusual Volume for June 21 - Equities.com
06/22/16 07:13 AMBrokers Issue Average Price Target Of 132.23 On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Fiscal Standard
06/22/16 07:13 AMAlnylam Readouts Offer 2017-2018 Catalysts - Seeking Alpha
06/21/16 02:24 PMMorning Watch List: Tesla Motors Inc (NASDAQ:TSLA), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Arena ... - KC Register
06/19/16 02:24 PMThis Weeks Broker Views For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Fiscal Standard
06/17/16 02:25 PMNotable Stocks within Investor Radar: Tenet Healthcare Corporation (NYSE:THC) , Alnylam Pharmaceuticals, Inc ... - Street Updates
06/17/16 02:25 PMBiotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx - PR Newswire (press release)
06/17/16 10:23 AMAlnylam Pharmaceuticals : Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
06/16/16 02:27 PMLarge Inflow of Money Witnessed in Alnylam Pharmaceuticals - Trade Calls
06/16/16 02:27 PMBRIEF-Alnylam Pharmaceuticals names David-Alexandre Gros Principal Financial Officer - Reuters
06/16/16 02:27 PMArbutus Biopharma Taken Off Of Chardan's Sell List - Benzinga
06/15/16 04:22 PMBRIEF-Alnylam Pharmaceuticals names David-Alexandre Gros Principal Financial Officer - * Appointed David-Alexandre Gros, M.D. Senior VP and chief business officer to serve as principal financial officer
06/15/16 03:32 PMALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/14/16 02:27 PMMost recent Trading report: ZIOPHARM Oncology Inc (NASDAQ:ZIOP) , Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Street Updates
06/13/16 07:31 AMAlnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : June 13, 2016 -
06/11/16 10:35 AMAlnylam Pharmaceuticals Inc.: Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal ... - The Wall Street Transcript
06/11/16 10:35 AMEarnings Trends of the Stocks: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Builders FirstSource, Inc. (NASDAQ ... - Beacon Chronicle
06/11/16 07:30 AMAlnylam Pharmaceuticals Inc Conference Call to Discuss Phase 1/2 Clinical Results with ALN-CC5 scheduled for 8:30 am ET today -
06/11/16 06:19 AMAlnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study - [at noodls] - 06.11.2016 - Initial Data Support Potential for ALN-CC5 to Reduce Dose and Frequency of Eculizumab - - Initial Results Also Support Potential for ALN-CC5 to Improve Disease Control in Eculizumab Inadequate ...
06/09/16 12:15 PMETF’s with exposure to Alnylam Pharmaceuticals, Inc. : June 9, 2016 -
06/09/16 12:15 PMETF’s with exposure to Alnylam Pharmaceuticals, Inc. : June 9, 2016 -
06/08/16 10:54 AMTwo Movers inside Traders Radar: Sequenom, Inc. (NASDAQ:SQNM) , Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Street Updates
06/07/16 08:02 PMRecent Update on Price Movements: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) , Alnylam Pharmaceuticals, Inc ... - Street Updates
06/06/16 12:01 PMRecent Update on Price Movements: BioMarin Pharmaceutical (BMRN) , Alnylam Pharmaceuticals, (ALNY) - Street Updates
06/04/16 07:45 PMAlnylam Pharmaceuticals, Inc. (ALNY) Earns Buy Rating from Needham & Company LLC - Let Me Know About This
06/04/16 10:53 AMAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Update & Estimates - Stock Tick Tock
06/03/16 08:28 PMAlnylam Pharmaceuticals Inc.: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data - The Wall Street Transcript
06/03/16 10:54 AMShare Rating Focus on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - HNN
06/03/16 10:54 AMStock To Watch: Alnylam Pharmaceuticals (ALNY) In Perilous Reversal - TheStreet.com
06/03/16 07:15 AMAlnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data - [at noodls] - 06.03.2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients ...
06/02/16 02:30 PMStrong Sell Calls Count For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) At 0 - Investor Newswire - Strong Sell Calls Count For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) At 0Investor NewswireAnalyst score was 1.25. A quarter ago, the mean score was 1.5 and 0 were Strong Sell recommendations. Strong Buy calls were 8, the buy calls were 0 and sell calls on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were 0. The count of Hold ratings was 1.and more »
06/02/16 11:06 AMTarget Price and Stock Performance Rundown for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - HNN - Target Price and Stock Performance Rundown for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Alnylam Pharmaceuticals, Inc.and more »
06/02/16 10:03 AM​Alnylam gains a cool $1.5B in market cap on bad news for rival -
06/01/16 02:29 PMComprehensive Report on: Calumet Specialty Products Partners LP (NASDAQ:CLMT), Alnylam Pharmaceuticals, Inc ... - Beacon Chronicle - Beacon ChronicleComprehensive Report on: Calumet Specialty Products Partners LP (NASDAQ:CLMT), Alnylam Pharmaceuticals, Inc ...Beacon ChronicleAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) currently has High Price Target of $180. The Low and Mean Price Targets are $63 and $120.5 respectively. These price targets are a consensus analysis of 12 brokers. When having a look at Recommendation ...and more »
06/01/16 02:29 PMAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Quarterly EPS Estimate At $-1.24 - Investor Newswire - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Quarterly EPS Estimate At $-1.24Investor NewswireFirst Call stated that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) can touch $120.50 in coming one year. For the next quarter, the per-share earnings target is $-1.24 and for ongoing fiscal at $-4.94. EPS target for next year is $-5.40 versus the mean ...and more »
06/01/16 10:48 AMHealthcare Worth Watching Stocks: BioMarin Pharmaceutical Inc.(NASDAQ:BMRN), Alnylam Pharmaceuticals, Inc ... - NYSE Journal (press release) - NYSE Journal (press release)Healthcare Worth Watching Stocks: BioMarin Pharmaceutical Inc.(NASDAQ:BMRN), Alnylam Pharmaceuticals, Inc ...NYSE Journal (press release)On Tuesday, Shares of BioMarin Pharmaceutical Inc.(NASDAQ:BMRN), added 0.63% and closed at $89.65 in the last trading session. The last trading range of the stock ranges between $88.94 and $91.25. BioMarin Pharmaceutical Inc. (BMRN) declared ...and more »
05/31/16 02:28 PMEarnings Trend of the Stock: Alnylam Pharmaceuticals (ALNY), Quest Diagnostics (DGX) - Beacon Chronicle - Beacon ChronicleEarnings Trend of the Stock: Alnylam Pharmaceuticals (ALNY), Quest Diagnostics (DGX)Beacon Chronicle... the Low Revenue estimate is $ 3.00 Million and High Revenue estimate is $ 11.10 Million. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) currently has High Price Target of $ 180.00. The Low and Mean Price Targets are $ 63.00 and $ 120.50 respectively.and more »
05/31/16 08:24 AMUnder Analysts Radar: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - The Point Review - The Point ReviewUnder Analysts Radar: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)The Point ReviewAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has grabbed the attention from analysts, when it saw a value decrease of -4.25 percent in the last trading session. A total of 1.24 million shares exchanged hands during the intra-day trade compared with its ...and more »
05/31/16 08:21 AMIonis’s Stock Tanks as GSK Withdraws from Phase 3 Study -
05/31/16 06:52 AMCould Alnylam Pharmaceuticals Change Medicine as We Know It? - A revolutionary way of approaching disease treatment could spell massive gains for early investors.
05/28/16 11:29 PMPerformance at a Glance on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - HNN - Performance at a Glance on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s stock has performed at various points in its past ...and more »
About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company's pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALNY
  • CUSIP: 02043Q10
Key Metrics:
  • Previous Close: $56.95
  • 50 Day Moving Average: $60.58
  • 200 Day Moving Average: $68.36
  • P/E Ratio: N/A
  • P/E Growth: -0.24
  • Market Cap: $4.65B
  • Current Quarter EPS Consensus Estimate: $-4.94 EPS
Additional Links:
Alnylam Pharmaceuticals (NASDAQ:ALNY) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha